The JAK-STAT3 pathway in ALK-negative ALCL is overactive owing to JAK1 and STAT3 mutations or fusion proteins of ROS1, TYK2, NFKB2, and NCOR2. This evidence concerns the gene ALK and anaplastic large cell lymphoma.